Ullman Reacts to Risks of Lax NDI Policy

December 8, 2020 | Compliance Investigations & White Collar

Marc Ullman, in the Nutraceuticals World article, “Dietary Supplement Leaders Lament Pitfalls of FDA’s Approach to NDIs,” expressed frustration that, despite several New Dietary Ingredient applications (NDIs) being rejected, a synthetic supplement with a history of adverse events in animal testing was allowed to reach the market. The article describes how the U.S. Food and Drug Administration’s relaxed posture toward companies that sidestep the NDI process in bringing their product to store shelves could endanger consumers.

Click here to read the article.

Share this article:

Related News

Get legal updates and news delivered to your inbox